Our vision is to advance healthcare everywhere by transforming data and local insights into scalable and sustainable solutions, delivered with trusted partners globally and in low‑ and middle‑income countries.
IQVIA is working with The Global Fund and (RED) to strengthen healthcare in low- and middle-income countries, especially in Africa. Projects like the Data Science Catalytic Fund, launched with Rwanda, aim to drive innovation and speed up disease outbreak response. Through collaboration and technology, IQVIA is helping tackle global health challenges.
IQVIA is working with Europe’s Health Emergency Preparedness and Response Authority (HERA), harnessing data to better identify and respond to future health threats.
The role of data in pandemic preparedness.
Avoiding potential health emergencies requires development, production and distribution of medical countermeasures (MCM), including medicines, vaccines, diagnostic tests, and masks. HERA also has a coordination role, working with European Member States and agencies including the European Centre for Disease Prevention and Control and the European Medicines Agency. Together they gather data on health threats, European stocks of MCM and relevant response capabilities.
The Advanced Technology for Health Intelligence and Action IT system (Athina) is critical in bringing together intelligence on Europe’s pandemic preparedness. IQVIA helped define the appropriate real-world datasets to track MCM supply chains. We are also enabling the tracking of MCM shortages and identification of potential vulnerabilities and strategic dependencies, giving HERA the insight it needs to strengthen Europe’s future response.
Since 2022, there has been a steady increase in mpox cases and deaths in the Democratic Republic of the Congo (DRC), which in 2024 spread to multiple countries and developed into a full-scale healthcare emergency. Vaccinations are a powerful tool to prevent infection and control disease spread. As part of efforts to develop a new mpox vaccine, we partnered with a major pharmaceutical company to rapidly launch effectiveness trials during the outbreak. Using our GRAM (Geographic Risk Assessment and Mitigation) approach, we identified trial sites in Kinshasa and Goma, DRC, accelerating vaccine development.
Improve surveillance to address a global threat.
In September 2024, the UN General Assembly convened leaders from politics, healthcare, and life sciences to set new goals and actions to address antimicrobial resistance (AMR).
The University of Liverpool’s Civic Health Innovation Labs, funded by the UK Office for Life Sciences, is developing an antimicrobial learning system using IQVIA’s Health Analytics Network to improve antibiotic prescribing practices and reduce resistance. IQVIA also built a customizable forecast model to estimate demand for injectable antibiotics, validated in eight countries and adaptable for use in low- and middle-income regions.
The role of strategic partnerships to act fast.
In conjunction with national and regional collaborators, IQVIA and the Coalition for Epidemic Preparedness Innovations (CEPI) are working to enhance the world’s preparedness to rapidly conduct life-saving clinical research for vaccines and other biological countermeasures against emerging infectious diseases.
Furthermore, in the following nine days after the first patient, the coalition of partners supported the enrollment of an additional 700 subjects in the trial. This speed was facilitated by the years of investment we have made establishing relationships, local talent and technical capabilities in Africa and due to strategic partnerships already in place with CEPI and the Government of Rwanda.